Results 81 to 90 of about 6,883,814 (290)

Identification of a Shiga toxin A‐derived peptide internalized into Gb3 receptor‐bearing cells via interaction with the Shiga toxin B subunit

FEBS Letters, EarlyView.
The process of internalization of the Shiga toxin A subunit via formation of a complex with the Shiga toxin B subunit, which specifically binds to the Gb3 receptor. The peptide is designed to act as a carrier of drugs into cancer cells. Here, we explored the potential of peptides derived from the catalytic A subunit of Shiga toxin (STxA) to be drug ...
Giulia Opassi, João C. Encarnação, Valeria Napolitano, Grzegorz Dubin, Grzegorz Popowicz, Karl Andersson, U. Helena Danielson   +6 more
wiley   +1 more source

[Molecular targeted therapy].

Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen, 2006
Until recently, cancer therapy was based on three modalities: surgery, radiotherapy, and cytostatic chemotherapy. In most instances treatment of solid tumors was a surgical domain. For patients with incomplete resection or relapse after surgery, radiotherapy and chemotherapy usually offered only partial response and mostly of limited duration.
Stenner-Liewen F, Zippelius A, Pestalozzi BC, Knuth A   +3 more
openaire   +4 more sources

KNTC1 initiates a KNTC1/E2F8/MYC positive feedback loop to facilitate tumorigenesis and enhance chemoresistance in bladder cancer

Journal of Experimental & Clinical Cancer Research
Background Bladder cancer (BLCA) is a lethal malignancy frequently challenged by chemoresistance and limited therapeutic options. Kinetochore-associated 1 (KNTC1) has been implicated in cancer, yet its precise role, regulatory mechanism, and therapeutic ...
Kailai Chen, Hecheng Su, Feng Pei, Xi Chen, Meiqi Xu, Fang Chai, Yakun Luo   +6 more
doaj   +1 more source

Targeting RAF dimers in RAS mutant tumors: From biology to clinic

Acta Pharmaceutica Sinica B
RAS mutations occur in approximately 30% of tumors worldwide and have a poor prognosis due to limited therapies. Covalent targeting of KRAS G12C has achieved significant success in recent years, but there is still a lack of efficient therapeutic ...
Huanhuan Yin, Qiulin Tang, Hongwei Xia, Feng Bi   +3 more
doaj   +1 more source

SMURF1 facilitates estrogen receptor ɑ signaling in breast cancer cells

Journal of Experimental & Clinical Cancer Research, 2018
Background Estrogen receptor alpha (ER alpha) is expressed in the majority of breast cancers and promotes estrogen-dependent cancer progression. ER alpha positive breast cancer can be well controlled by ER alpha modulators, such as tamoxifen.
Huijie Yang, Na Yu, Juntao Xu, Xiaosheng Ding, Wei Deng, Guojin Wu, Xin Li, Yingxiang Hou, Zhenhua Liu, Yan Zhao, Min Xue, Sifan Yu, Beibei Wang, Xiumin Li, Gang Niu, Hui Wang, Jian Zhu, Ting Zhuang   +17 more
doaj   +1 more source

Investigating transcription factor dynamics in health and disease using FRAP

FEBS Letters, EarlyView.
FRAP analysis of GFP‐tagged transcription factors reveals how molecular mobility and target engagement change in response to drug treatment. By combining live‐cell imaging, quantitative model fitting, and statistical analysis, this approach uncovers transcription factor dynamics linked to disease mechanisms, providing a powerful framework for ...
Kannan Govindaraj, Carolina Vazquez Garzon, Jose Joaquin Velasco, Janine N. Post   +3 more
wiley   +1 more source

Microbiome‐blood–brain barrier interactions in aging — mechanisms and therapeutic potential

FEBS Letters, EarlyView.
Aging reshapes the gut microbiome (↓SCFA‐producing commensals; ↑pro‐inflammatory outputs), shifting circulating metabolites (↓SCFAs; ↑LPS, ↑TMAO, ↑PAA) that act at the BBB to increase nonspecific transcytosis, alter transport, and promote astrocyte reactivity, heightening brain vulnerability.
Daniel Cuervo‐Zanatta, Hari Baskar Balasubramanian, Amir Pasokh, Marietta Zille   +3 more
wiley   +1 more source

Current Targeted Therapy for Metastatic Colorectal Cancer

, 2023
Colorectal cancer (CRC) is the third most common type of cancer and the second leading cause of cancer deaths worldwide. Surgery or surgery plus radiotherapy and/or chemotherapy for patients with metastatic CRC (mCRC) were accepted as the main ...
Kato, Yukinari, Ohishi, Tomokazu, Yukihiro Yoshida, Kaneko, Mika K., Yoshida, Yukihiro, Mika K. Kaneko, Atsuo Takashima, Tomokazu Ohishi, Yukinari Kato, Takashima, Atsuo, Manabu Kawada, Kawada, Manabu   +11 more
core   +1 more source

An epithelial GPR35 isoform supports tumor‐associated transcriptional and metabolic phenotypes

FEBS Letters, EarlyView.
GPR35 generates two functionally distinct isoforms with previously unresolved roles. GPR35‐short mediates immune‐cell chemotaxis, while GPR35‐long is enriched in colorectal cancer epithelium, where it supports increased metabolism, proliferation, and tumor‐associated transcriptional programs.
Jørgen D. Rønneberg, Martine Hjeltnes, Josephine Krieger, Joshua E. Elias, Maria Stensland, Kristian Holm, Xiaojun Jiang, Chuki Khangsar, Tuula A. Nyman, Arthur Kaser, Johannes R. Hov, Tom H. Karlsen, Nicole C. Kaneider, Frode L. Jahnsen, Georg Schneditz   +14 more
wiley   +1 more source

Structure‐forward targeting of claudins with synthetic binders

FEBS Letters, EarlyView.
Claudins form the paracellular barriers between epithelial and endothelial tissues at tight junctions and are targets for molecular binders with the goal of modulating barrier permeability. Claudin‐binding molecules are relevant in drug delivery or in altering claudin interactions with disease‐causing proteins.
Alex J. Vecchio
wiley   +1 more source